Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
The trial will be led by Baylor College of Medicine and will include US and international clinical sites from university-based hospitals and cooperative networks.
- The trial will be led by Baylor College of Medicine and will include US and international clinical sites from university-based hospitals and cooperative networks.
- The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required.
- Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
- For more information on GP2 immune response and clinical data, please visit the Companys clinical trial tab at https://greenwichlifesciences.com/clinical-trials/ .